AcoMed Completes Over RMB 100 Million Series B Financing to Expand Full-Portfolio Neurovascular Intervention Platform

Recently, VCBeat learned that AccuMedical Beijing Ltd. (hereinafter referred to as “AccuMedical”) has completed a Series B financing round exceeding RMB 100 million. The lead investor was Sequoia Capital China Fund, with Huagai Capital participating as a co-investor. Joywise Capital served as the exclusive financial advisor for this round of financing.

AccuMedical, founded in 2016 and headquartered in Beijing, China, with its R&D center located in California, USA, is a company offering a full product line in the field of neurointervention.

China is one of the countries with the highest incidence of stroke (commonly known as “apoplexy”) worldwide. For 20 consecutive years, it has been the leading cause of death among Chinese patients, with an overall mortality and disability rate exceeding 60%. The China Stroke Prevention and Treatment Report (2018) indicates that by 2030, there will be 31.77 million stroke patients nationwide. Currently, both the number of prevalent stroke cases and the mortality rate per 100,000 people surpass those of cardiovascular diseases. However, due to constraints such as treatment costs, the limited number of surgeons capable of performing these procedures, and insufficient penetration of specialized services into lower-tier healthcare facilities, the annual volume of neurointerventional procedures remains only at the level seen in cardiac interventions in 2004. With strengthened support from medical policies, a shorter learning curve for surgical techniques, and favorable factors including clinical trial data, neurointervention is poised to enter a “golden decade.”

The “Outline of the Healthy China 2030 Plan” has elevated stroke prevention and control to a national strategy. In addition to policy and strategic impetus, the field of neurointervention is experiencing rapid development. However, due to the high precision required during procedures, the market share of domestic brands remains low. The market is dominated by giants such as Medtronic, Stryker, Johnson & Johnson, and Terumo, who collectively hold over 90% of the market share.

In this fast-growing sector, AccuMedical has completed innovative designs for multiple products, leveraging its R&D team with a global perspective and its deep understanding of pain points in clinical applications, thereby securing approval through the National Medical Products Administration’s “Green Channel.”

The founder of AccuMedical stated that, in the Chinese market, domestically produced medical devices in the new era should not be mere replicas of imported products. Regardless of whether they are domestically produced or imported, Chinese doctors and patients deserve access to the best products available globally. AccuMedical is committed to leveraging the respective strengths of China and the United States to place the world’s most advanced neurointerventional devices into the hands of Chinese physicians.

We sincerely appreciate the investors’ trust and recognition, and we also thank our existing shareholders for their continued support.

Yang Yunxia, Managing Director at Sequoia Capital China, stated, “Cerebrovascular diseases represent a major threat to public health. Neurointerventional techniques hold promise for treating a significant proportion of these conditions with greater efficiency and safety. The AccuMedical team boasts extensive R&D experience and clearly defined product technological advantages. We look forward to collaborating with the AccuMedical team and our fellow investors to drive the company’s rapid growth and deliver higher-quality products and services to patients.”

Meng Nan, Executive General Manager of Huagai Capital’s Healthcare Fund, stated: “AccuMedical ranks among the industry leaders in neurointerventional devices, boasting top-tier R&D capabilities and a robust sales resource network. The company’s U.S.-based R&D team has extensive experience in full-cycle product development; its first intracranial aneurysm flow diverter to enter clinical trials has obtained innovative medical device designation and garnered high recognition from clinicians. Meanwhile, the management team demonstrates mature channel expansion capabilities, promising a clear commercialization pathway post-launch. AccuMedical is poised to become a truly resilient leading enterprise in the neurointerventional field. Huagai Capital will continue to create business synergy opportunities to support the company’s growth.”

Yang Zhenjun, Partner at Haoyue Capital, stated, “Haoyue Capital is honored to have assisted AccuMedical in completing this round of financing. An outstanding company requires not only robust R&D capabilities but also forward-looking strategic vision, a distinguishing characteristic that sets exceptional enterprises apart and has earned high recognition from top-tier investment institutions. With the successful completion of this financing round and the accelerated development of the company’s product pipeline, product registration and market launch are imminent. We believe that, leveraging its technological advantages and with capital support, AccuMedical can significantly expand and strengthen its product portfolio, emerging as a leading enterprise in the neurointerventional field.”